Retrospective study to assess the impact of ranibizumab 0.5mg in visual acuity of patients with macular diseases, referred to Professor Edgard Santos University Hospital and Oftalmodiagnose Eye Hospital, in the state of Bahia, Brazil

Session Details

Session Title: Free Paper Session 11: Vascular Diseases & Diabetic Retinopathy III

Session Date/Time: Friday 08/09/2017 | 11:00-12:30

Paper Time: 12:18

Venue: Room 114

First Author: : B.Rodrigues BRAZIL

Co Author(s): :    A. Castelo Branco   I. Mendes   C. Koch   B. Amaral   L. Costa                 

Abstract Details

Purpose:

The primary objective of the study is to evaluate, in a population in the state of Bahia, Brazil, the impact of ranibizumab in best-corrected visual acuity of patients with macular disease and macular edema, in a real life context.

Setting:

We review data of patients diagnosed with macular diseases,followed at the Professor Edgard Santos University Hospital and Oftalmodiagnose, between April 2011 and April 2012, who have received one or more ranibizumab injections with documented follow-up to the end of their treatment .

Methods:

This is a retrospective, observational study (non-interventionist). Pertinent data were retrospectively collected. The visual acuity were measured by the Snellen chart, before and after treatment in the population. Considering the universe of 238 patients with macular diseases treated, the sample size calculation based on the estimated proportion of the population, at a confidence level of 95% and an acceptable error of 5% as a result, presented a sample of at least 147 patients.

Results:

A total of 238 patients were screened, and 147 of these were enrolled. Eighty-three percent of patients under 59 years, and 79% of patients up 59 years, maintained or improved vision in the period of the follow up. The statistical test was performed with a confidence level of 95% and significance level (α) of 5%. The software used was SPSS 20.0.

Conclusions:

There was a satistically significant impact in visual acuity of sample patientes after treatment with ranibizumab in a real life context.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy